Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
VTRS beats Q4 estimates on 5% revenue growth, boosted by strong Brands sales and Greater China gains, while returning over $1B to shareholders in 2025.
Zacks·4d ago
More News
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·4d ago
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates
Viatris (VTRS) delivered earnings and revenue surprises of +9.62% and +5.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
Viatris Posts Narrower Loss In Q4; Expects Workforce Reduction Of Up To Approx. 10%
(RTTNews) - Viatris Inc. (VTRS) reported a fourth quarter net loss of $340.1 million or $0.30 per share compared to a loss of $516.5 million or $0.43 per share, prior year. The company said loss in...
Nasdaq News: Markets·4d ago
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend PR Newswire PITTSBURGH, Feb. 26, 2026...
PR Newswire·4d ago
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia FDA Accepts Viatris Supplemental New Drug Application for...
PR Newswire·5d ago
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Zacks·6d ago
Unveiling Viatris (VTRS) Q4 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Viatris (VTRS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks·7d ago
What's in Store for These 5 Medical Companies This Earnings Season?
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.